Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$19.90M+326.04%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Dror Bashan
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 226
- Beta
- 0.01
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 0.89
Financials
Revenue
$19.90M+326.0%Net Income
$3.78MEBITDA
$5.76MFree Cash Flow
$-10.99MEPS (diluted)
$0.05Shares Outstanding (diluted)
82.56M+727.1%Operating Expenses
$7.46MCash & Debt
$40.66MRevenue by Segment (annual)
$52.74MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $52.74M | $-6.60M | $-0.08 |
| 2024 | $53.40M | $2.93M | $0.04 |
| 2023 | $65.49M | $8.31M | $0.12 |
| 2022 | $47.64M | $-14.93M | $-0.31 |
| 2021 | $38.35M | $-27.58M | $-0.62 |
| 2020 | $62.90M | $-6.52M | $-0.22 |
| 2019 | $54.69M | $-18.28M | $-1.23 |
| 2018 | $34.24M | $-26.46M | $-1.80 |
| 2017 | $21.08M | $-83.44M | $-6.50 |
| 2016 | $9.20M | $-29.36M | $-0.29 |
| 2015 | $4.36M | $58.04M | $0.61 |
| 2014 | $15.16M | $-29.94M | $-0.32 |
| 2013 | $11.51M | $-27.79M | $-0.30 |
| 2012 | $34.42M | $-11.62M | $-1.30 |
Valuation
PLXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-53.85%Social Signal Score
Mentions (3)
- Newsseekingalpha.com·19d ago·Positive
Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Protalix BioTherapeutics, Inc. (PLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·54d ago·Positive
Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript Protalix BioTherapeutics, Inc. (PLX) Q2 2026 Earnings Call Transcript
View source ↗ - Newsprnewswire.com·55d ago·Negative
Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results Company to host conference call and webcast today at 8:00 a.m. EDT Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4 million from the second quarter of 2025, driven primarily by sales of Elfabrio® Total revenue climbed to $53.6 million, year to date, from $25.8 million for the same period in 2025, which includes the previously reported $25.0 million Chiesi milestone pay
View source ↗
Earnings
Thu, Nov 12(in 5 weeks)
Consensus estimate $-0.02 per share
Typical surprise -50.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$0.05 vs $-0.01beat
- Wed, May 13$0.22 vs $-0.01beat
- Wed, Mar 18$-0.07 vs $0.01miss
- Thu, Nov 13$0.03 vs $0.06miss
- Thu, Aug 14$0.00 vs $0.03miss
- Fri, May 9$-0.05 vs $0.08miss
Estimates and results for PLX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PLX officers and directors.
- Bought
- $811k
- Sold
- $2.1m
7 trades
3 trades
- Bashan Drorbought
- Bar-shalev Amossold
- Schwartz Aharonbought
- Bashan Drorbought
- Bashan Drorbought
- Schwartz Aharonbought
- Bashan Drorbought
- Dexcel Pharma Technologies Ltd.sold
90 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PLX.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.